Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development

Written By Mollie Rotmensch

Gui X. et al. Cancer Immunol. Res. 2019; 7: 1244-1257.

Mollie Rotmensch
Previous

Phagocytosis checkpoints as new targets for cancer immunotherapy
Next

Targeting the immune inhibitory receptor LILRB4 to treat acute myeloid leukemia (AML)